Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
grade F 4.63 -2.32% -0.11
NVAX closed down 2.32 percent on Thursday, October 17, 2019, on 44 percent of normal volume.

Earnings due: Nov 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NVAX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -2.32%
NR7 Range Contraction -2.32%
NR7-2 Range Contraction -2.32%
Wide Bands Range Expansion -2.32%
Oversold Stochastic Weakness -2.32%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.14%
Narrow Range Bar Range Contraction -4.14%
NR7 Range Contraction -4.14%

Older signals for NVAX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Influenza Vaccination Vaccines Influenza Vaccine Rabies Seasonal Influenza H5n1 Clinical Trials Virus Like Particle
Is NVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 51.6
52 Week Low 4.01
Average Volume 955,670
200-Day Moving Average 13.9742
50-Day Moving Average 5.699
20-Day Moving Average 5.224
10-Day Moving Average 4.718
Average True Range 0.3448
ADX 21.46
+DI 19.6422
-DI 29.1419
Chandelier Exit (Long, 3 ATRs ) 6.1056
Chandelier Exit (Short, 3 ATRs ) 5.4244
Upper Bollinger Band 6.5725
Lower Bollinger Band 3.8755
Percent B (%b) 0.28
BandWidth 51.627106
MACD Line -0.3442
MACD Signal Line -0.3028
MACD Histogram -0.0413
Fundamentals Value
Market Cap 1.34 Billion
Num Shares 290 Million
EPS -0.77
Price-to-Earnings (P/E) Ratio -6.01
Price-to-Sales 13.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.99
Resistance 3 (R3) 5.00 4.90 4.93
Resistance 2 (R2) 4.90 4.80 4.89 4.91
Resistance 1 (R1) 4.76 4.75 4.71 4.75 4.89
Pivot Point 4.66 4.66 4.63 4.65 4.66
Support 1 (S1) 4.52 4.57 4.47 4.51 4.37
Support 2 (S2) 4.42 4.51 4.41 4.35
Support 3 (S3) 4.28 4.42 4.33
Support 4 (S4) 4.27